Clinical Trials are an integral part of Primary Sclerosing Cholangitis (PSC) research. Currently, there are three clinical trials being organized by Mayo Clinic's PSC research team.
Ongoing Clinical Trials
This pilot study is looking at the effects of curcumin on the changes to alkaline phosphatase in PSC patients. Curcumin is a naturally occurring anti-oxidant with anti-inflammatory properties.
This phase II, randomized, placebo-controlled clinical trial is designed to examine the safety, tolerability and efficacy of daily dosing (over an 18-month period) with oral vancomycin, using a stepped-up dosing strategy with three increasing doses, on the clinical course, and the progression of PSC, and to compare the treated patients with those on placebo.
This translational study seeks to generate the first, multi-omics and comprehensive clinical data resource for PSC. The study aims to define the bigger-picture cellular networks and gene-environment interactions driving PSC by integrating several layers of -omics data. In so doing, we will identify molecular disease signatures, including environmental toxins, metabolism-related chemicals and gut bacteria, unique to PSC patients.
Clinical Trials and PSC
In the following video, Dr. John E. Eaton details the importance of clinical trials in PSC research.
In this video, Dr. Eaton describes the challenges in developing clinical trials for PSC research.
Send an email to invite people you know to join the Primary Sclerosing Cholangitis (PSC) page.